Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
The University of Texas MD Anderson Cancer Center
Abstract
PURPOSE No established treatment exists for pancreatic neuroendocrine tumor (NET) progression after failure of chemotherapy. Everolimus (RAD001), an oral inhibitor of mammalian target of rapamycin, in combination with octreotide has demonstrated encouraging antitumor activity in patients with NETs. PATIENTS AND METHODS This open-label, phase II study assessed the clinical activity of everolimus in patients with metastatic pancreatic NETs who experienced progression on or after chemotherapy. Patients were stratified by prior octreotide therapy (stratum 1: everolimus 10 mg/d, n = 115; stratum 2: everolimus 10 mg/d plus octreotide long-acting release [LAR], n = 45). Tumor assessments (using Response Evaluation…
Citation impact
- FWCI
- 40.79
- Percentile
- 100%
- References
- 38
Authors
19- JCJames C. YaoCorresponding
The University of Texas MD Anderson Cancer Center
- CLCatherine Lombard‐Bohas
The University of Texas MD Anderson Cancer Center
- ÉBÉric Baudin
The University of Texas MD Anderson Cancer Center
- LKLarry K. Kvols
The University of Texas MD Anderson Cancer Center
- PRPhilippe Rougier
The University of Texas MD Anderson Cancer Center
Topics & keywords
- Everolimus
- Medicine
- Octreotide
- Neuroendocrine tumors
- Internal medicine
- Progressive disease
- Gastroenterology
- Chemotherapy
- Good health and well-being